managing-anticoagulation-therapy

name	managing-anticoagulation-therapy
description	Guides anticoagulation selection, dosing, monitoring, and bridging protocols. Use when managing warfarin, DOACs, or heparin therapy, or planning periprocedural anticoagulation.
tags	["management","pharmacy"]
metadata	{"author":"casemark","practice_areas":["Clinical Pharmacy","Pharmacy"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Anticoagulation Therapy

Guides anticoagulation selection, dosing, monitoring, and bridging protocols for warfarin, DOACs, and heparin therapy.

Why This Skill Exists

Anticoagulants are consistently ranked among the top high-alert medications by the Institute for Safe Medication Practices (ISMP). Warfarin alone accounts for more emergency department visits for adverse drug events than any other medication class in patients over 65. Dosing errors, inadequate monitoring, and improper periprocedural management lead to catastrophic bleeding events or thromboembolic strokes.

The complexity of anticoagulation management spans multiple dimensions: selecting the appropriate agent based on indication (atrial fibrillation, VTE, mechanical heart valve), renal-adjusted dosing for DOACs, INR-based warfarin titration, weight-based heparin nomograms, bridging decisions for surgical patients, and reversal agent selection during active bleeding. The Joint Commission National Patient Safety Goal NPSG.03.05.01 specifically addresses anticoagulation safety, and accredited institutions must maintain anticoagulation management protocols. Pharmacist-managed anticoagulation clinics consistently demonstrate superior time-in-therapeutic-range (TTR) compared to physician-only management.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the indication for anticoagulation? (Default: atrial fibrillation; alternatives: VTE treatment, VTE prophylaxis, mechanical heart valve, LV thrombus)
2. Which anticoagulant is being used or considered? (Default: review all options for indication)
3. What is the patient's renal function (SCr, CrCl by Cockcroft-Gault, eGFR)? (Default: request labs)
4. What is the patient's weight? (Default: actual body weight for heparin dosing)
5. Is there an upcoming procedure requiring bridging assessment? (Default: no)
6. What is the patient's bleeding risk score (HAS-BLED for AF)? (Default: calculate from available data)
7. What is the patient's stroke risk score (CHA₂DS₂-VASc for AF)? (Default: calculate from available data)
8. Are there concomitant antiplatelet agents, NSAIDs, or interacting drugs? (Default: check active med list)

Documents to Request

• Complete medication profile including OTC/herbals
• Labs: CBC with platelet count, PT/INR, aPTT, SCr/BUN, LFTs, anti-Xa level if applicable
• CHA₂DS₂-VASc and HAS-BLED score components
• Surgical/procedural schedule if applicable
• Prior anticoagulation history (INR diary, prior bleeding/clotting events)
• Body weight (actual and adjusted if obese)

---

Step 1: Indication-Based Agent Selection

Match indication to appropriate anticoagulant options:

Indication	Preferred Agents	Contraindicated
Non-valvular AF	Apixaban, rivaroxaban, dabigatran, edoxaban, warfarin	—
Mechanical heart valve	Warfarin (target INR 2.5-3.5)	All DOACs (RE-ALIGN trial)
Acute VTE treatment	Apixaban, rivaroxaban (single-drug), LMWH→dabigatran/edoxaban, LMWH→warfarin	—
VTE prophylaxis (surgical)	Enoxaparin, rivaroxaban, apixaban (indication-specific)	—
Heparin-induced thrombocytopenia	Argatroban, bivalirudin	Heparin, LMWH, warfarin (acute phase)
Antiphospholipid syndrome (triple-positive)	Warfarin (INR 2-3)	DOACs (TRAPS trial)

Calculate risk stratification scores:

• CHA₂DS₂-VASc: CHF(1), HTN(1), Age≥75(2), DM(1), Stroke/TIA(2), Vascular disease(1), Age 65-74(1), Sex female(1)
• HAS-BLED: HTN(1), Abnormal renal/liver(1 each), Stroke(1), Bleeding(1), Labile INR(1), Elderly>65(1), Drugs/alcohol(1 each)

---

Step 2: Dosing and Renal Adjustment

Warfarin: Initiate 5 mg daily (2.5 mg for elderly, malnourished, liver disease, CYP2C9/VKORC1 polymorphisms). Check INR at day 3-5, adjust by 10-20% increments.

DOAC Renal-Adjusted Dosing:

Drug	Standard Dose (AF)	Renal Adjustment
Apixaban	5 mg BID	2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, SCr ≥1.5
Rivaroxaban	20 mg daily with food	15 mg daily if CrCl 15-50 mL/min
Dabigatran	150 mg BID	75 mg BID if CrCl 15-30 mL/min; avoid if <15
Edoxaban	60 mg daily	30 mg daily if CrCl 15-50 mL/min, weight ≤60 kg, or P-gp inhibitor

Weight-based heparin nomogram (VTE): 80 units/kg bolus → 18 units/kg/hour infusion. Check aPTT at 6 hours. Adjust per institution-specific nomogram targeting aPTT 1.5-2.5x control or anti-Xa 0.3-0.7 IU/mL.

Enoxaparin: 1 mg/kg SC BID (treatment) or 40 mg SC daily (prophylaxis). Reduce to 1 mg/kg daily if CrCl <30 mL/min. Monitor anti-Xa in obesity (>120 kg), renal impairment, and pregnancy.

---

Step 3: Monitoring and Therapeutic Targets

Agent	Monitoring Parameter	Target	Frequency
Warfarin	PT/INR	2.0-3.0 (most); 2.5-3.5 (mechanical valve)	Daily inpatient → weekly → monthly
Heparin UFH	aPTT or anti-Xa	aPTT 1.5-2.5x control; anti-Xa 0.3-0.7	q6h until stable, then daily
Enoxaparin	Anti-Xa (select populations)	0.5-1.0 IU/mL (BID dosing peak, 4h post)	At steady state in special populations
DOACs	Generally not monitored	Drug-specific anti-Xa or dTT if needed	Pre-procedure or suspected toxicity

Monitor for bleeding: daily hemoglobin, stool guaiac, urinalysis, neurological checks for ICH risk.

---

Step 4: Periprocedural Bridging Protocol

Apply the BRIDGE trial framework for AF patients on warfarin:

• Low thromboembolic risk (CHA₂DS₂-VASc 1-4): No bridging; hold warfarin 5 days pre-procedure
• High thromboembolic risk (mechanical valve, recent VTE <3 months, CHA₂DS₂-VASc ≥7): Consider bridging with enoxaparin 1 mg/kg BID, last dose 24h pre-procedure

DOAC perioperative management: Hold based on renal function and bleeding risk:

• Low bleeding risk: hold 24-48 hours
• High bleeding risk: hold 48-72 hours
• Dabigatran in CrCl <50: hold 72-96 hours

---

Step 5: Reversal and Emergency Management

Agent	Reversal	Dose
Warfarin	Vitamin K (IV), 4-factor PCC	Vitamin K 10 mg IV; PCC per INR-based dosing
Dabigatran	Idarucizumab	5 g IV (two 2.5 g boluses)
Apixaban/Rivaroxaban	Andexanet alfa or 4-factor PCC	Andexanet per package insert; PCC 25-50 units/kg
UFH	Protamine	1 mg per 100 units heparin (max 50 mg)
Enoxaparin	Protamine (partial)	1 mg per 1 mg enoxaparin (<8h); 60-80% reversal

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the selected agent appropriate for the indication (no DOACs for mechanical valves)?
2. Has renal function been calculated and dose adjusted per CrCl thresholds?
3. Are drug interactions with the anticoagulant identified and managed?
4. Is the monitoring plan specific with parameters, targets, and frequencies?
5. Has bleeding risk been formally scored and documented?

---

Quality Audit

• Indication verified and matched to guideline-recommended agent
• CHA₂DS₂-VASc and HAS-BLED scores calculated (for AF patients)
• Renal function assessed by Cockcroft-Gault for DOAC dosing
• Correct dose selected with renal/weight/age adjustments applied
• Drug interactions screened (CYP3A4/P-gp for DOACs, CYP2C9/VKORC1 for warfarin)
• Monitoring plan includes specific lab parameters and frequency
• Bridging plan documented for periprocedural patients with risk justification
• Reversal strategy identified and agents available for the selected anticoagulant
• Patient education on signs of bleeding and dietary considerations (warfarin/vitamin K)
• Transition plan documented for hospital discharge or agent switching
• Duration of therapy defined (3 months VTE vs. indefinite AF)
• ISMP high-alert medication safeguards addressed

---

Guidelines

• Always use Cockcroft-Gault CrCl (not CKD-EPI eGFR) for DOAC dose adjustment—trials used this equation
• Never use DOACs in mechanical heart valve patients (contraindicated per RE-ALIGN)
• Warfarin TTR should exceed 65%; consider DOAC switch if persistently below target
• Weight-based heparin dosing should use actual body weight; cap initial bolus at institutional limits for morbid obesity
• Document CHA₂DS₂-VASc, HAS-BLED, and rationale when anticoagulation is deferred despite indication
• Periprocedural bridging is generally NOT recommended for AF patients at moderate thromboembolic risk per BRIDGE trial
• Always verify DOAC dose is not inappropriately reduced—underdosing increases stroke risk without reducing bleeding
• Ensure reversal agents are stocked and protocols are accessible for emergency bleeding management